Clinical Trials Register

Summary
EudraCT Number:	2022-000899-19
Sponsor's Protocol Code Number:	EVX-01-001
National Competent Authority:	France - ANSM
Clinical Trial Type:	EEA CTA
Trial Status:	Ongoing
Date on which this record was first entered in the EudraCT database:	2022-07-12
Trial results

Index
A. PROTOCOL INFORMATION
B. SPONSOR INFORMATION
C. APPLICANT IDENTIFICATION
D. IMP IDENTIFICATION
D.8 INFORMATION ON PLACEBO
E. GENERAL INFORMATION ON THE TRIAL
F. POPULATION OF TRIAL SUBJECTS
G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
P. END OF TRIAL

Expand All Collapse All

A. Protocol Information

A.1

Member State Concerned

France - ANSM

A.2

EudraCT number

2022-000899-19

A.3

Full title of the trial

An open label, single arm trial evaluating the efficacy and safety of EVX-01 in combination with pembrolizumab in checkpoint inhibitor treatment naïve adults with unresectable or metastatic melanoma

A.3.1

Title of the trial for lay people, in easily understood, i.e. non-technical, language

A single arm trial evaluating the efficacy and safety of EVX-01 in combination with
pembrolizumab in adults with unresectable or metastatic melanoma

A.4.1

Sponsor's protocol code number

EVX-01-001

A.5.3

WHO Universal Trial Reference Number (UTRN)

U1111-1272-6176

A.7

Trial is part of a Paediatric Investigation Plan

A.8

EMA Decision number of Paediatric Investigation Plan

B. Sponsor Information
B.Sponsor: 1
B.1.1	Name of Sponsor	EVAXION BIOTECH A/S
B.1.3.4	Country	Denmark
B.3.1 and B.3.2	Status of the sponsor	Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1	Name of organisation providing support	EVAXION BIOTECH A/S
B.4.2	Country	Denmark
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1	Name of organisation	EVAXION BIOTECH A/S
B.5.2	Functional name of contact point	Agon Hyseni
B.5.3	Address:
B.5.3.1	Street Address	Dr. Neergaards Vej 5F
B.5.3.2	Town/ city	Hoersholm
B.5.3.3	Post code	DK-2970
B.5.3.4	Country	Denmark
B.5.4	Telephone number	+453133 85 98
B.5.6	E-mail	clinicaltrials@evaxion-biotech.com

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3	IMP Role	Test
D.2	Status of the IMP to be used in the clinical trial
D.2.1	IMP to be used in the trial has a marketing authorisation	No
D.2.5	The IMP has been designated in this indication as an orphan drug in the Community	No
D.2.5.1	Orphan drug designation number
D.3 Description of the IMP
D.3.1	Product name	EVX-01
D.3.2	Product code	EVX-01
D.3.4	Pharmaceutical form	Solution for injection
D.3.4.1	Specific paediatric formulation	No
D.3.7	Routes of administration for this IMP	Intramuscular use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	Not applicable
D.3.9.2	Current sponsor code	EVX-01
D.3.9.3	Other descriptive name	EVX-01
D.3.9.4	EV Substance Code	SUB269335
D.3.10	Strength
D.3.10.1	Concentration unit	µg/ml microgram(s)/millilitre
D.3.10.2	Concentration type	equal
D.3.10.3	Concentration number	100
D.3.11 The IMP contains an:
D.3.11.1	Active substance of chemical origin	No
D.3.11.2	Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)	Yes
	The IMP is a:
D.3.11.3	Advanced Therapy IMP (ATIMP)	No
D.3.11.3.1	Somatic cell therapy medicinal product	No
D.3.11.3.2	Gene therapy medical product	No
D.3.11.3.3	Tissue Engineered Product	No
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device)	No
D.3.11.3.5	Committee on Advanced therapies (CAT) has issued a classification for this product	No
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy	No
D.3.11.5	Radiopharmaceutical medicinal product	No
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)	Yes
D.3.11.7	Plasma derived medicinal product	No
D.3.11.8	Extractive medicinal product	No
D.3.11.9	Recombinant medicinal product	No
D.3.11.10	Medicinal product containing genetically modified organisms	No
D.3.11.11	Herbal medicinal product	No
D.3.11.12	Homeopathic medicinal product	No
D.3.11.13	Another type of medicinal product	Yes
D.3.11.13.1	Other medicinal product type	The active substance has chemical origin, even it is an Immunological medicinal product (vaccine). To solve the EudraCT validation error, D.3.11.2 has been chosen Yes and D.3.11.1 No.
D.IMP: 2
D.1.2 and D.1.3	IMP Role	Test
D.2	Status of the IMP to be used in the clinical trial
D.2.1	IMP to be used in the trial has a marketing authorisation	Yes
D.2.1.1.1	Trade name	KEYTRUDA
D.2.1.1.2	Name of the Marketing Authorisation holder	Merck Sharp & Dohme Limited
D.2.1.2	Country which granted the Marketing Authorisation	European Union
D.2.5	The IMP has been designated in this indication as an orphan drug in the Community	No
D.2.5.1	Orphan drug designation number
D.3 Description of the IMP
D.3.1	Product name	Keytruda
D.3.2	Product code	L01FF02
D.3.4	Pharmaceutical form	Solution for infusion
D.3.4.1	Specific paediatric formulation	No
D.3.7	Routes of administration for this IMP	Intravenous use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8	INN - Proposed INN	Pembrolizumab
D.3.9.1	CAS number	1374853-91-4
D.3.9.2	Current sponsor code	MK-3475
D.3.9.4	EV Substance Code	SUB167136
D.3.10	Strength
D.3.10.1	Concentration unit	mg milligram(s)
D.3.10.2	Concentration type	equal
D.3.10.3	Concentration number	100
D.3.11 The IMP contains an:
D.3.11.1	Active substance of chemical origin	No
D.3.11.2	Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)	Yes
	The IMP is a:
D.3.11.3	Advanced Therapy IMP (ATIMP)	No
D.3.11.3.1	Somatic cell therapy medicinal product	No
D.3.11.3.2	Gene therapy medical product	No
D.3.11.3.3	Tissue Engineered Product	No
D.3.11.3.4	Combination ATIMP (i.e. one involving a medical device)	No
D.3.11.3.5	Committee on Advanced therapies (CAT) has issued a classification for this product	No
D.3.11.4	Combination product that includes a device, but does not involve an Advanced Therapy	No
D.3.11.5	Radiopharmaceutical medicinal product	No
D.3.11.6	Immunological medicinal product (such as vaccine, allergen, immune serum)	No
D.3.11.7	Plasma derived medicinal product	No
D.3.11.8	Extractive medicinal product	No
D.3.11.9	Recombinant medicinal product	Yes
D.3.11.10	Medicinal product containing genetically modified organisms	No
D.3.11.11	Herbal medicinal product	No
D.3.11.12	Homeopathic medicinal product	No
D.3.11.13	Another type of medicinal product	No

D.8 Information on Placebo

E. General Information on the Trial

E.1 Medical condition or disease under investigation

E.1.1

Medical condition(s) being investigated

unresectable or metastatic melanoma

E.1.1.1

Medical condition in easily understood language

a type of skin tumor

E.1.1.2

Therapeutic area

Diseases [C] - Cancer [C04]

MedDRA Classification

E.1.3

Condition being studied is a rare disease

E.2 Objective of the trial

E.2.1

Main objective of the trial

To evaluate if EVX-01 improves the best overall response (BOR) in patients with an initial assessment of stable disease (SD) or partial response (PR) after initiating pembrolizumab treatment, as compared to historical outcomes with pembrolizumab alone in metastatic or unresectable melanoma

E.2.2

Secondary objectives of the trial

-To evaluate if EVX-01 in combination with pembrolizumab improves the overall response rate, as compared to historical outcomes with pembrolizumab alone in metastatic or unresectable melanoma
-To evaluate if EVX-01 improves the progression free survival (PFS) in patients with an initial assessment of SD or PR after initiating pembrolizumab treatment, as compared to historical outcomes with pembrolizumab alone in metastatic or unresectable melanoma
-To evaluate if EVX-01 in combination with pembrolizumab improves the overall survival (OS), as compared to historical outcomes with pembrolizumab alone in metastatic or unresectable melanoma
-To evaluate the safety of EVX-01 in patients with metastatic or unresectable
melanoma on pembrolizumab treatment
-To evaluate the immunologic response induced by EVX-01
-To evaluate the feasibility of manufacturing EVX-01

E.2.3

Trial contains a sub-study

E.3

Principal inclusion criteria

1. The patient (or legally acceptable representative if applicable) provides written
informed consent for the trial.
2. Be ³ 18 years of age on day of signing informed consent.
3. Histologically confirmed, and not amenable to local therapy, metastatic or
unresectable melanoma Stage III or Stage IV, as per AJCC 8th ed. staging system.
a. Patient may not have a diagnosis of uveal or ocular melanoma.
b. Patients must be treatment naïve to checkpoint inhibitor (CPI) therapy
c. Patients must have testing for a BRAF mutation prior to trial entry. Patients
with BRAF V600E mutant melanoma may have received prior BRAF
inhibitor therapy as first-line systemic therapy and be eligible for this trial as
second line treatment. At the discretion of the investigator, patients with
BRAF V600E mutant melanoma who have NOT received a BRAF inhibitor
are also eligible for this trial as first-line treatment if they meet the following
additional criteria:
i. LDH < local ULN at screening
ii. No clinically significant tumor related symptoms in the judgment of the investigator
iii. Absence of rapidly progressing metastatic melanoma in the judgment of the investigator
4. Have measurable disease per RECIST 1.1 as assessed by the local site investigator
within 4 weeks prior to trial allocation. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
5. Patients must be willing and able to provide fresh tumor tissue from an unresectable or metastatic site of disease for neoepitope and biomarker analyses.
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 4
weeks prior to trial allocation.
7. A male patient must agree to use contraception and refrain from sperm donation during
the treatment period and for at least 120 days after the last dose of trial treatment.
Contraceptive use by men should be consistent with local regulations regarding the
methods of contraception for those participating in clinical studies.
8. A female patient is eligible to participate if she is not pregnant, not breastfeeding, and
at least one of the following conditions applies:
a. Not a woman of childbearing potential (WOCBP)
b. A WOCBP who agrees to follow contraceptive guidance during the treatment
period and for at least 120 days after the last dose of trial treatment.
Contraceptive use by women should be consistent with local regulations
regarding the methods of contraception for those participating in clinical
studies.
9. Absence of any condition hampering compliance with the trial protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
10. Have adequate organ function . Specimens must be collected within 10 days prior to trial allocation.
11. Human immunodeficiency virus (HIV) infected patients must be on anti-retroviral
therapy (ART) and have a well-controlled HIV infection/disease defined as:
a. Patients on ART must have a CD4+ T-cell count >350 cells/mm3 at time of
screening
b. Patients on ART must have achieved and maintained virologic suppression
defined as confirmed HIV RNA level below 50 copies/mL or the lower limit of
qualification (below the limit of detection) using the locally available assay at the
time of screening and for at least 12 weeks prior to trial allocation
c. Patients on ART must have been on a stable regimen, without changes in drugs or
dose modification, for at least 4 weeks prior to trial allocation
12. Patients who are HBsAg positive are eligible if they have received HBV antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior
to trial allocation.
13. Patients with history of HCV infection are eligible if HCV viral load is undetectable at screening.

E.4

Principal exclusion criteria

-A WOCBP who has a positive urine pregnancy test (within 72 hours) prior to first dose of trial treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137).
-Has received prior systemic anticancer therapy including investigational agents within 4 weeks prior to first dose of trial treatment.
- Has received prior radiotherapy within 2 weeks prior to first dose of trial treatment. Patients must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1-week washout is permitted for palliative radiation (≤2 weeks of radiotherapy) to non-CNS disease.
-Has received a live or live-attenuated vaccine within 30 days prior to the first dose of trial intervention.
-Is currently participating in or has participated in a trial of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of trial treatment.
-Has had an allogeneic tissue/solid organ transplant.
-Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
-Has a known additional malignancy that is progressing or has required active treatment within the past 3 years prior to trial allocation.
- Known CNS metastases and/or carcinomatous meningitis.
- Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.
-Has an active autoimmune disease that has required systemic treatment in past 2 years prior to trial allocation (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
-Has a history of (non-infectious) pneumonitis / interstitial lung disease that required
steroids or has current pneumonitis / interstitial lung disease.
- Has an active infection requiring systemic therapy.
- HIV-infected participants with a history of Kaposi sarcoma and/or Multicentric Castleman Disease.
- Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator.
-Has a known psychiatric or substance abuse disorder that would interfere with the patient’s ability to cooperate with the requirements of the trial.

E.5 End points

E.5.1

Primary end point(s)

Composite of a BOR of CR or PR for patients with SD at the time of EVX-01 administration and a BOR of CR for patients with PR at the time of EVX-01 administration, during 24 months of treatment with pembrolizumab, as per RECIST 1.1 criteria.

E.5.1.1

Timepoint(s) of evaluation of this end point

The final analysis on the primary endpoint will be conducted after all patients have either completed the approximately two-year treatment with pembrolizumab or have been censored due to an event before.

E.5.2

Secondary end point(s)

•Overall response rate, defined as the proportion of the patients in the analysis population who have best response as CR or PR assessed 24 months after initiation of treatment with pembrolizumab as per RECIST 1.1 criteria
• PFS assessed 24 months after initiation of treatment with pembrolizumab and defined as the time from initiation of pembrolizumab treatment to the first documented disease progression per RECIST 1.1. criteria or death due to any causes, whichever occurs first
• OS, assessed 24 months after initiation of treatment with pembrolizumab and defined as the time from initiation of treatment of pembrolizumab to death due to any cause
• Number, type and severity of AEs and SAEs
• Level of immunologic response toward EVX-01 measured by CD4+ and CD8+ neoepitope specific lymphocytes, assessed throughout dosing with EVX-01

E.5.2.1

Timepoint(s) of evaluation of this end point

The final analysis on the sec. endpoint will be conducted after all patients have either completed the approximately two-year treatment with pembrolizumab or have been censored due to an event before.

E.6 and E.7 Scope of the trial

E.6

Scope of the trial

E.6.1

Diagnosis

E.6.2

Prophylaxis

E.6.3

Therapy

E.6.4

Safety

Yes

E.6.5

Efficacy

Yes

E.6.6

Pharmacokinetic

Yes

E.6.7

Pharmacodynamic

Yes

E.6.8

Bioequivalence

E.6.9

Dose response

E.6.10

Pharmacogenetic

E.6.11

Pharmacogenomic

E.6.12

Pharmacoeconomic

E.6.13

Others

Yes

E.6.13.1

Other scope of the trial description

Immunogenicity

E.7

Trial type and phase

E.7.1

Human pharmacology (Phase I)

E.7.1.1

First administration to humans

E.7.1.2

Bioequivalence study

E.7.1.3

Other

E.7.1.3.1

Other trial type description

E.7.2

Therapeutic exploratory (Phase II)

Yes

E.7.3

Therapeutic confirmatory (Phase III)

E.7.4

Therapeutic use (Phase IV)

E.8 Design of the trial

E.8.1

Controlled

E.8.1.1

Randomised

E.8.1.2

Open

Yes

E.8.1.3

Single blind

E.8.1.4

Double blind

E.8.1.5

Parallel group

E.8.1.6

Cross over

E.8.1.7

Other

E.8.2

Comparator of controlled trial

E.8.2.1

Other medicinal product(s)

Information not present in EudraCT

E.8.2.2

Placebo

E.8.2.3

Other

E.8.3

The trial involves single site in the Member State concerned

E.8.4

The trial involves multiple sites in the Member State concerned

Yes

E.8.4.1

Number of sites anticipated in Member State concerned

E.8.5

The trial involves multiple Member States

Yes

E.8.5.1

Number of sites anticipated in the EEA

E.8.6 Trial involving sites outside the EEA

E.8.6.1

Trial being conducted both within and outside the EEA

Yes

E.8.6.2

Trial being conducted completely outside of the EEA

E.8.6.3

If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned

Australia

United States

France

Spain

Italy

E.8.7

Trial has a data monitoring committee

Yes

E.8.8

Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial

LPLV

E.8.9 Initial estimate of the duration of the trial

E.8.9.1

In the Member State concerned years

E.8.9.1

In the Member State concerned months

E.8.9.1

In the Member State concerned days

E.8.9.2

In all countries concerned by the trial years

E.8.9.2

In all countries concerned by the trial months

E.8.9.2

In all countries concerned by the trial days

F. Population of Trial Subjects

F.1 Age Range

F.1.1

Trial has subjects under 18

F.1.1.1

In Utero

F.1.1.2

Preterm newborn infants (up to gestational age < 37 weeks)

F.1.1.3

Newborns (0-27 days)

F.1.1.4

Infants and toddlers (28 days-23 months)

F.1.1.5

Children (2-11years)

F.1.1.6

Adolescents (12-17 years)

F.1.2

Adults (18-64 years)

Yes

F.1.2.1

Number of subjects for this age range:

F.1.3

Elderly (>=65 years)

F.1.3.1

Number of subjects for this age range:

F.2 Gender

F.2.1

Female

Yes

F.2.2

Male

Yes

F.3 Group of trial subjects

F.3.1

Healthy volunteers

F.3.2

Patients

Yes

F.3.3

Specific vulnerable populations

Yes

F.3.3.1

Women of childbearing potential not using contraception

F.3.3.2

Women of child-bearing potential using contraception

Yes

F.3.3.3

Pregnant women

F.3.3.4

Nursing women

F.3.3.5

Emergency situation

F.3.3.6

Subjects incapable of giving consent personally

F.3.3.7

Others

F.4 Planned number of subjects to be included

F.4.1

In the member state

F.4.2

For a multinational trial

F.4.2.1

In the EEA

F.4.2.2

In the whole clinical trial

F.5

Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)

None

G. Investigator Networks to be involved in the Trial
G.4 Investigator Network to be involved in the Trial: 1

N. Review by the Competent Authority or Ethics Committee in the country concerned

Competent Authority Decision

Authorised

Date of Competent Authority Decision

2022-12-09

Ethics Committee Opinion of the trial application

Favourable

Ethics Committee Opinion: Reason(s) for unfavourable opinion

Date of Ethics Committee Opinion

2022-11-15

P. End of Trial
P.	End of Trial Status	Ongoing

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA

Clinical trials